Stivarga

Summary

Name(s) Target Manufacturer Status
Stivarga, regorafenib FLT1, KDR, FLT4, KIT, TEK, PDGFRB, PDGFRA, FGFR1, FGFR2, NTRK1, MAPK11, BRAF, ABL1, EPHA2, RAF1, RET, FRK Bayer AG FDA approved for: Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST)

Clinical Trials

Suggested Reading / Relevant Literature

#